MEDVF
vs
S&P 500

Over the past 5 years, MEDVF has underperformed S&P 500, delivering a return of -94% compared to the S&P 500's 81% growth.

Stocks Performance
MEDVF vs S&P 500

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Performance Gap
MEDVF vs S&P 500

Performance Comparison
MEDVF vs S&P 500

1 Month 3 Months 6 Months 1 Year 5 Years 10 Years 20 Years
MEDVF
Medivolve Inc
-17%
0%
25%
-67%
-94%
-92%
-100%
S&P 500
Market Index
-3%
3%
7%
24%
81%
186%
389%

Medivolve Inc
Glance View

Market Cap
16.3m USD
Industry
Health Care

Medivolve, Inc. engages in seeking technologies, ground-breaking innovations, and exclusive partnerships to help combat COVID-19 and generate risk-adjusted returns for investors. The company is headquartered in Toronto, Ontario. The company went IPO on 2009-11-16. The firm is engaged in providing telehealth platform, a clinical diagnostic network, and a data driven artificial intelligence (AI) framework to improve patient care. The company offers a network of retail collection sites, which provides clinical services in diagnostic testing, vaccinations, and other point-of-care services. The company is also engaged in developing technologies to identify, treat, and prevent medical issues. The company provides solution in COVID-19 testing, immunity scoring, and vaccinations. Its COVID-19 Testing includes rapid antibody blood test, reverse transcription (RT)- polymerase chain reaction (PCR) test and antigen test. The firm uses channel partner Aditxt Therapeutics, Inc. (Aditxt) to offer COVID-19 immunity status monitoring through its mobile testing centers.

MEDVF Intrinsic Value
0.004 USD
Overvaluation 26%
Intrinsic Value
Price

See Also

Back to Top